Extended Data Fig. 8: Anti GD3 targeting in vivo restore NK cell functionality locally in vivo and ex vivo.
a, Lung weight at d27 after instillation with Bleomycin in function of the treatment with the anti-GD3 antibody. b, Analysis of the immune infiltration in the lungs by flow cytometry of isotypic control or anti GD3 mAb treated fibrotic mice used in Fig. 7a-h. c, Evaluation by flow cytometry of the percentage of CD69+ activated intrapulmonary NK cells at d27; data corresponding to Fig. 7e. d, Density plot for the quantification of NK degranulation corresponding to the Fig. 4e. e, Determination of the quantity of NK cells within the lung of fibrotic mice depending on the treatment. f, Determination of the intrapulmonary NK cell functionality ex vivo from treated or control mice against YAC-1 cells after 4 hours of rechallenge. g, Determination of the quantity of NK cells within the spleen of fibrotic mice depending on the treatment. h, Determination of the NK cell functionality ex vivo from the spleen of treated or control mice against YAC-1 cells after 4 hours of rechallenge. i, j, NK cell functionality after 24 hours of culture without MRC5 (controls data corresponding to Fig. 2). Experiment done on n > 6 mice (a-h); Experiment done on n = 3 experiment (a-h). *p < 0.05, **p < 0.01, and ***p < 0.001; two-tailed Mann–Whitney U test.
